Skip to content
Biodatica
Start free

Investigator

C Ronald Kahn

JOSLIN DIABETES CENTER · funded by NIDDK, NIGMS

Companies
3

Resolved onto their grants.

Grants
6

Federal awards on file.

Non-dilutive funding
$3.4M

Summed across those awards.

First award
Apr 1, 1982

Latest Sep 17, 2021.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance

    $593k

    Sep 17, 2021NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11127512 (opens the source filing in a new tab)

  2. R35

    Signaling mechanisms that detect stress and maintain homeostasis

    $517k

    Jul 20, 2017NIGMSJOSLIN DIABETES CENTERNIH RePORTER · 11171608 (opens the source filing in a new tab)

  3. R35

    Signaling mechanisms that detect stress and maintain homeostasis

    $27k

    Jul 20, 2017NIGMSJOSLIN DIABETES CENTERNIH RePORTER · 11376332 (opens the source filing in a new tab)

  4. R01

    Developmental genes, miRNAs and adipose tissue

    $701k

    Dec 14, 2009NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11086048 (opens the source filing in a new tab)

  5. R01

    Developmental genes, miRNAs and adipose tissue

    $701k

    Dec 14, 2009NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11330394 (opens the source filing in a new tab)

  6. R01

    The Insulin Receptor and Its Signaling Mechanisms

    $866k

    Apr 1, 1982NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11296313 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources